FDA Grants Priority Review To Pfizer’s RSV Vax With May Decision Timeline

FDA has granted priority review designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate for people ages 60 and older, with a goal of making an approval decision by May 2023, the company announced Wednesday (Dec. 7) . Pfizer said in August that it planned to submit its application for FDA approval "in the coming months.” The company is in the race to develop the first FDA-approved RSV vaccine. FDA also granted priority review to GlaxoSmithKline’s RSV vaccine candidate in...